#### RESEARCH



# Human protozoa infection and dysplasia in ulcerative colitis: a neglected aspect in a prominent disease

Enas F. Abdel Hamed<sup>1</sup> · Nahed E. Mostafa<sup>1</sup> · Shaimaa M. Farag<sup>1</sup> · Mohamed N. Ibrahim<sup>2</sup> · Basma H. Ibrahim<sup>3</sup> · Hayam E. Rashed<sup>3</sup> · Mona Radwan<sup>4</sup> · Salem Y. Mohamed<sup>5</sup> · Ramy El Hendawy<sup>6</sup> · Eman M. Fawzy<sup>1</sup>

Received: 15 May 2023 / Accepted: 6 September 2023 / Published online: 15 September 2023  $\ensuremath{\textcircled{}}$  The Author(s) 2023

### Abstract

The chance of getting colorectal cancer (CRC) is higher in people with chronic ulcerative colitis (UC). The impact of parasitic infections on UC is underappreciated. The purpose of this study was to look into the effect of intestinal protozoal infections on the dysplastic changes generated by UC. The research included 152 adult patients with histologically confirmed UC and 152 healthy controls. Fecal samples were examined for the presence of parasites and fecal calprotectin (FC). The enzyme-linked immunosorbent assay measured serum anti-p53 antibodies (p53Abs) and metallothioneins (MTs). The advanced oxidation protein products (AOPPs) and reduced glutathione (GSH) levels were measured by a spectrophotometric method in all subjects. Serum C-reactive protein (CRP) and IL-6 were also measured. In addition, histopathological and immunohistochemical investigations of intestinal tissue were done. Our results exhibited significant increases in FC and CRP, IL-6, AOPPs, MTs, and p53Abs in ulcerative colitis patients with parasitic infections compared to those without parasites. In contrast, GSH levels showed a significant decrease in the same group compared with other groups. Histopathological and immunohistochemical assessments of intestinal tissue signified severe inflammation and strong expression of PD-L1 in patients with parasitic infections compared to others without parasitic infections. Our research indicated a greater frequency of intestinal protozoa in UC patients with elevated inflammatory and dysplastic biomarker levels. This suggests that these parasites may be involved in the etiology of chronic UC and the associated carcinogenetic process. This is the first report of a link between parasitic infections and dysplastic alterations in UC patients.

Keywords Ulcerative colitis · Protozoal infections · Dysplasia · FC · AOPPs · MTs · p53Abs · PD-L1

Section Editor: Bradford McGwire

Enas F. Abdel Hamed drenasfakhry@gmail.com

- <sup>1</sup> Department of Medical Parasitology, Faculty of Medicine, Zagazig University, El Kawmia Square, Zagazig, Sharkia Governorate, Egypt
- <sup>2</sup> Clinical Laboratories Department, College of Applied Medical Sciences, Jouf University, Qurrayat, Kingdom of Saudi Arabia
- <sup>3</sup> Department of Pathology, Faculty of Medicine, Zagazig University, Zagazig, Sharkia, Egypt
- <sup>4</sup> Department of Community and Occupational Medicine, Faculty of Medicine, Zagazig University, Zagazig, Sharkia, Egypt
- <sup>5</sup> Department of Internal Medicine, Gastroenterology & Hepatology Unit, Zagazig University, Zagazig, Egypt
- <sup>6</sup> Department of Tropical Medicine, Zagazig University, Zagazig, Egypt

# Introduction

Ulcerative colitis is a type of chronic inflammatory bowel disease (IBD) causing superficial damage to the mucosal layer of the colon and rectum (Ungaro et al. 2017). Chronic diarrhea and fecal blood are these patients' most common clinical features. UC patients are expected to have a 2.4fold greater CRC risk than the general population (Jess et al. 2012). Early onset IBD appears to be associated with an increased risk of CRC (Olén et al. 2020). In addition to CRP and FC, serum sIL-2R and IL-6 levels can be used to determine disease activity status in UC patients (Mavropoulou et al. 2020). Inhibition of inflammation has therapeutic benefits as it affects the steps of tumor development, including initiation, promotion, invasion, and metastasis (Romano et al. 2016). Biscaglia et al. (2021) reported that 25 IBD-CRC patients had their 39 genes implicated in cancer predisposition.

Over 450 million people are infected with intestinal parasites (Pestehchian et al. 2015). Infections with *Cryptosporidium* spp occurred more frequently in patients with colorectal cancer than in controls, regardless of age or gender (Sulżyc-Bielicka et al. 2018). Sawant et al. (2020) hypothesize an association between human cryptosporidiosis and colon cancer, while more than 20% of the world's cancer burden is attributed to infectious pathogens. Colorectal cancer is the most common cancer linked to *Cryptosporidium* infection. In addition, it has been linked to an increased risk of *Cryptosporidium* spp. and *Blastocystis hominis* infections (Sulżyc-Bielicka et al. 2021; Taghipour et al. 2022).

Oxidative stress is an imbalance between prooxidants and antioxidants, intimately linked to inflammatory processes associated with the development and exacerbation of IBD (Tian et al. 2017). Advanced oxidation protein products are new oxidative stress protein markers with pro-inflammatory properties. Moreover, because AOPP accumulation promotes the development of IBD, so, it can be used as a noninvasive activation marker (Alagozlu et al. 2013).

Glutathione is one of the most prevalent thiol antioxidants in cells (Braidy et al. 2019). In addition, it has critical enzymatic defense mechanisms within the mucosa of colon that preserves proteins in their reduced form (Morgenstern et al. 2003). So, it protects cells from reactive oxygen species (ROS) connected to cancer development (Liu et al. 2018).

Every living organism contains metallothioneins, a class of tiny proteins involved in crucial biological processes such as cell replication and apoptosis (Cioffi et al. 2004). In pathological situations, such as different cancer kinds, serum MT levels are markedly elevated (Krizkova et al. 2010). Na et al. (2017) hypothesized the connection between metallothioneins and colon cancer as its development enhanced the expression of metallothioneins.

The most often reported somatic gene mutations in human cancer are p53 gene mutations, which increase p53 gene outputs in cancerous cells. This can trigger an immunological reaction by producing circulating anti-p53 antibodies (Hamouda et al. 2011). However, most TP53 mutations in CRC are missense mutations that compromise the function of wild-type p53. As a result, it boosts cancer cell stemness, proliferation, invasion, and metastasis, which aid in developing the disease (Liebl and Hofmann 2021).

This study aimed to look into the possible relationship between intestinal protozoal infections and the inflammatory and dysplastic alterations in ulcerative colitis.

# Subjects and methods

Our research was carried out at Zagazig University's Department of Parasitology, Faculty of Medicine, from January 2021 to January 2022. It was authorized by the Medical Ethics Committee of Zagazig University's Faculty of Medicine in compliance with the Helsinki Declaration. It was registered at the Institutional Review Board (IRB) #9855-9-1-2022. The patients and controls provided both informed and written permission. The Montreal categorization of the degree and severity of UC was used. Standard clinical, endoscopic, radiographic, and pathological criteria were used to confirm the diagnosis of UC (Silverberg et al. 2005). Procolitis, left sided colitis, and severe or pancolitis are all UC categories.

# **Study population**

This is a prospective case-control study that included 152 normal controls (GI) and 152 ulcerative colitis cases. Of the 152 cases with UC, 45 were free of parasitic infection (GII), and 107 were infected with parasites (GIII). During the initial enrollment visit, a gastroenterologist performed a full demographic and clinical exam for controls and patients.

#### Patients with IBD

Inclusion criteria: (i) For at least 3 months, IBD was diagnosed using the standard Montreal classification (Satsangi et al. 2006). (ii) IBD patients with ileocolic or colic locations. (iii) Patients ranging in age from 25 to 60.

Exclusion criteria: (i) Using antibiotics or any other probiotic bacterial supplement in the previous 3 months. (ii) Nonsteroidal anti-inflammatory medicines were used in the previous 3 months. (iii) A recent (within the last 3 months) diagnosis of gastrointestinal bacterial or parasite infections.

#### Controls (CTRLs)

Inclusion criteria: (i) Subjects with asymptomatic gastrointestinal disease (using a questionnaire to rule out any chronic conditions and present gastrointestinal complaints). (ii) Individuals under the age of 60 who get a colonoscopy to check for colorectal cancer. (iii) Absence of any macroscopic lesions including the diverticulae. (iv) Histological evaluation of intestinal biopsy samples obtained during colonoscopy revealed the absence of microscopic lesions.

Exclusion criteria: (i) Using antibiotics or any other probiotic bacterial supplement in the previous 3 months. (ii) Nonsteroidal anti-inflammatory medicines were used in the previous 3 months. (iii) A recent (within the last 3 months) diagnosis of gastrointestinal bacterial or parasite infections. (iv) Severe psychiatric disorder as the primary clinical concern. (v) Any other serious illnesses, as well as a history of drug or alcohol abuse.

#### Sample collection

In the current study, three stool samples were collected from both control participants and UC patients for parasitological investigation to detect intestinal pathogenic protozoa. Controls and patients were instructed to bring a stool sample from their morning stool immediately after their initial consultation or throughout their inpatient stay for fecal calprotectin measurement, according to Bathe et al. (2019). Iodine-staining smears (King 1975) and the formalin-ethyl acetate concentration technique were used to identify protozoa in stool samples (Truant et al. 1981; Henricksen and Pohlenz 1981). For *Cryptosporidium parvum* (*C. parvum*) detection, a modified Ziehl–Neelsen technique was used. The stained smears were scanned for the presence of the parasite using the 100-oil immersion lens.

#### Surveillance colonoscopy

All patients had a colonic biopsy conducted consistent with published American gastroenterological association recommendations for UC surveillance colonoscopy (Winawer et al. 2003). The formalin-fixed colon samples were sent for histological assessment by the pathologist. Throughout the endoscopy, serum samples were collected from each patient and stored at -80 °C until use.

#### Measurement of serological biomarkers

(1) Serum AOPP level estimation according to Witko-Sarsat et al. (1998), (2) serum GSH level was detected by spectrophotometry, in which 5.5'-dithiobis (2-nitrobenzoic acid) is reduced by GSH, which results in the formation of a yellow molecule. A commercial kit (Bio Diagnostic, Egypt) was used to quantify the reduced chromogen's absorbance at 405 nm, which is proportional to the GSH concentration (Sedlak and Lindsay 1968). (3) Determining the serum metallothionein level: After removing coexisting antibody-reactive protein using an acid (1 mol/L HCl) and heat (100 °C, 10 min) treatment, MTs in the blood were measured using an ELISA kit from RayBiotech, Inc. (Cousins 1991). (4) Serum p53Ab assay: p53Abs were identified using a commercially available ELISA kit (Quantikine) provided by Clinilab (Kirsch and Kastan 1998). The absorbance cutoff value was computed using the manufacturer's instructions (cutoff = 26.3).

#### The immunohistochemical study

The immunohistochemistry staining was carried out as follows: It was carried out using an automated immunostainer (Ventana BenchMark XT; USA). Sections were deparaffinized with xylene, rehydrated with alcohol, and saturated with 0.03% hydrogen peroxide, subsequently undergoing antigen retrieval. The main antibodies used were anti-p53, a mouse monoclonal antibody (Ab-6, clone DO-1, dilution 1:30, Thermo Scientific Lab Vision), and anti-PD-L1 in dilution of 1:100 (M3653, clone 22C3, Dako, Glostrup, Denmark). The ultraView Universal DAB Detection Kit was used. Finally, the sections were counterstained with hematoxylin and mounted in DPX. PD-L1 staining within the lamina propria was assessed separately and categorized according to the percentage of positive inflammatory cells within the entire area of the lamina propria as 0: negative, 1: 0.1-1%, 2: > 1-5%, 3: > 5-50%, and 4: > 50%PD-L1 (Jakubowska et al. 2016); P53 positive: strong staining to moderate staining in dysplastic cells; P53 negative: no staining or weakness or patchiness (Jung et al. 2014). PDL1 was diluted at a 1:100 ratio. PDL1 was diluted as (1:100). PD-L1 was assessed as negative, weak positive which was defined as a membranous or cytoplasmic PD-L1 expression in 1 to 49% of tumor cells, and PD-L1 strong positive was defined as expression in  $\geq 50\%$  of tumor cells at higher power magnification. In this work, negative and weak positive stain was considered as a negative group (Aron et al. 2015).

#### Data analysis

The analysis was performed using SPSS Statistics 23.0 (IBM Corp 2015). Data were summarized using descriptive statistics. Student's t test was used to compare continuous data. The Kruskal-Wallis test was used instead as a nonparametric test. Logistic regression analysis was used to detect the independent factors in the ulcerative colitis.

# Results

# The prevalence of parasitic infections and Montreal's classification of the UC patients

The most commonly identified parasites in GIII were *Blastocystis* in 52.33% of cases, followed by *Giardia lamblia*, *Cryptosporidium*, *Entamoeba histolytica/dispar*, and *Endolimax nana* in 20.56%, 14.95%, 6.54%, and 1.86% of cases, respectively. In keeping with Montreal's classification of the UC patients (severity), in GIII, the percentage severity (S3) was 83.2%, while it was 31.1% in GII. The mean age of GIII was 37.1  $\pm$  8.7, while that of GII was 44.0  $\pm$  9.2 at the time of the index colonoscopy, with a statistically significant difference between both groups (p < 0.0001) (Table 1; Fig. 1).

| Table 1 | The demographic features, | Montreal classifications, a | nd prevalence of parasi | tic infections in the groups analyzed |
|---------|---------------------------|-----------------------------|-------------------------|---------------------------------------|
|---------|---------------------------|-----------------------------|-------------------------|---------------------------------------|

| Characteristics                    | Control individuals $(n = 152)$ | UC patients without parasites $(n = 45)$ | UC patients with parasites $(n = 107)$ | t-test      | <i>p</i> -value |
|------------------------------------|---------------------------------|------------------------------------------|----------------------------------------|-------------|-----------------|
| Current age                        | $44.2 \pm 10.0$                 | 47.4 ± 9.8                               | 45.1 ± 7.9                             | 1.98        | 0.14            |
| Gender                             |                                 |                                          |                                        |             |                 |
| Male                               | 83 (54.6%)                      | 20 (44.4%)                               | 38 (35.5%)                             | $X^2 = 9.3$ | 0.01**          |
| Female                             | 69 (45.4%)                      | 25 (55.6%)                               | 69 (64.5%)                             |             |                 |
| Age at diagnosis $\pm$ SD          |                                 | $44.0 \pm 9.2$                           | $37.1 \pm 8.7$                         | 4.4         | 0.000***        |
| Montreal classification (extent)   |                                 |                                          |                                        |             |                 |
| Procolitis E1                      |                                 | 6 (13.3%)                                | 9 (8.4%)                               | 40.0        | 0.000***        |
| Left sided E2                      |                                 | 28 (62.2%)                               | 16 (15.0%)                             |             |                 |
| Pancolitis E3                      |                                 | 11 (24.4%)                               | 82 (76.6%)                             |             |                 |
| Montreal classification (severity) |                                 |                                          |                                        |             |                 |
| Mild (S1)                          |                                 | 9 (20.0%)                                | 7 (6.5%)                               | 39.8        | 0.000***        |
| Moderate (S2)                      |                                 | 22 (48.9%)                               | 11 (10.3%)                             |             |                 |
| Severe (S3)                        |                                 | 14 (31.1%)                               | 89 (83.2%)                             |             |                 |
| Parasitic infection                |                                 |                                          |                                        |             |                 |
| Blastocystis spp                   |                                 |                                          | 56 (52.33%)                            |             |                 |
| Giardia lamblia                    |                                 |                                          | 22 (20.56%)                            |             |                 |
| Cryptosporidium                    |                                 |                                          | 16 (14.95%)                            |             |                 |
| Entamoeba histolytica/dispar       |                                 |                                          | 7 (6.54%)                              |             |                 |
| Endolimax nana                     |                                 |                                          | 2 (1.86%)                              |             |                 |
| Co-infection with 2 parasites      |                                 |                                          | 4 (3.73%)                              |             |                 |

\*\*p-value < 0.01; \*\*\*p-value < 0.001

#### The fecal and serological biomarkers

The FC values in GIII patients were noticeably more outstanding than in GI l. Serum CRP, IL-6, AOPP, MT, and p53Abs values were significantly elevated in patients with UC (GII and GIII), with considerably higher values in GIII than in those of GII. On the other hand, a significant decrease in serum GSH level was obtained in GII, with significantly lower values in GIII. There were statistically significant differences between the two groups (Table 2).

# The univariate and multivariate analyses of the groups studied

Using univariate and multivariate analysis, a statistically significant difference in fecal calprotectin and serum levels of CRP, IL6, AOPP, MT, and P53 in GIII were obtained compared to GII. When the GHs are considered, readings in GIII are statistically significantly lower than in GII. Highly statistically significant CRP readings in GIII were 2.3 times higher than in GII. AOPP, MT, and P53 measurements in GIII were 54.3, 1.9, and 11.9 times higher than in GII, respectively. IL-6 levels in GIII were 1.4 times higher than in GII, with statistically significant differences. Fecal

calprotectin measurements in GIII were 1609 times higher than in GII, with vital statistical significance. The difference was highly statistically significant except for GSH, which was -0.7 times lower in GIII than in GII (Table 3).

# The histopathological and immunohistochemical studies of the individuals

Histopathological examination indicated severe inflammatory infiltration with significant mucosal ulceration in GIII (Fig. 2c) and a moderate inflammatory infiltrate with significant crypt distortion in GII (Fig. 2b), compared to normal colonic mucosa in GI (Fig. 2a). Moreover, mild dysplastic alterations (nuclear hyperchromatism and stratification) in GII (Fig. 2d) and severe dysplastic changes (marked nuclear hyperchromatism and pleomorphism) in GIII (Fig. 2e) were observed.

Immunostaining photomicrographs of PDLI and P53 colonic biopsies revealed significant PDLI expression with loss of membranous and cytoplasmic expression in colonic epithelium and considerable infiltration by PDL1-positive cells within the lamina propria in GIII (Fig. 2h). In GII, there was a moderate increase in PDL1-positive cell infiltration in the lamina propria (Fig. 2g) compared to negative PDL1 expression in GI (Fig. 2f). There was strong P53 expression in Fig. 2j and moderate P53 expression in Fig. 2i.




Fig. 1 a *Blastocyst* vacuolar form eosin stain (×40). b *Blastocyst* vacuolar form eosin stain (×100). c *Blastocyst* vacuolar form iodine stain (×100). d *Giardia lamblia* cyst form wet mount (×100). e *Giardia* 

#### *lamblia* trophozoite form wet mount (×100). **f** *Giardia lamblia* eosinstained cyst (×40). **g-h** *Cryptosporidium* iodine and Ziehl-Neelsen stain (×100). **i** *Entamoeba histolytica* trophozoite eosin stain (×100)

# Discussion

This study intended to explore the possible link between the inflammatory and dysplastic alterations in ulcerative colitis and intestinal protozoal infections. A positive association between parasitic infection and dysplastic changes in UC patients has been noted. Furthermore, Mostafa et al. (2018) confirmed the significant dysplastic alterations in the intestines of *Cryptosporidium*-infected mice. Moreover, CRC has been linked to an increased risk of *Cryptosporidium* spp. and *Blastocystis* spp infections (Taghipour et al. 2022).

One hundred seven of the 152 ulcerative colitis patients had parasite infections compared to controls. The most prevalent parasites were *Blastocystis* spp, *Giardia lamblia*, *Cryptosporidium*, *Entamoeba histolytica/dispar*, and *Endolimax nana*. These findings are consistent with those of Pestechian et al. (2021), who found a high prevalence of pathogenic intestinal protozoa in UC patients. In addition, *B. hominis* was detected more frequently in UC patients (Cekin et al. 2012). Our findings were significant and consistent with those of Toychiev et al. (2021), who confirmed the high prevalence of intestinal protozoa in ulcerative colitis and proposed anti-parasitic medication as a treatment option. In a case report, Pence et al. (2015) discovered that *B. hominis* may have a pathogenic effect.

According to the Montreal classification, S3 was found in 83.2% of GIII patients and 31.1% of GII patients. Iver et al. (2013) confirmed that parasites had a role in the exacerbation of UC. These findings might be explained by the fact infection with bacterial, viral, or parasitic agents alters gut flora, prompting the emergence of chronic inflammatory and UC problems. In our research, GIII had an intense inflammatory infiltrate with significant mucosal ulceration, whereas GII had a moderate inflammatory infiltrate with significant crypt deformation. Parasitic infections appear to exacerbate inflammatory biomarkers in UC patients. Highly statistically significant increases in fecal calprotectin, serum levels of IL-6, and CRP were obtained in GIII compared to GII. The disease activity in Crohn's disease (CD) and UC patients has been connected with serum levels of IL-6, soluble interleukin-2 receptor (sIL-2R), CRP, and FC values (Mavropoulou et al. 2020). Our findings may be explained by the fact that parasite protozoa change the structure of intestinal mucus and produce mucolytic enzymes, allowing their penetration

| Investigations             | Control individuals $(n = 152)$ | UC patients without parasites $(n = 45)$ | UC patients with parasites $(n = 107)$ | F-test    | <i>p</i> -value |
|----------------------------|---------------------------------|------------------------------------------|----------------------------------------|-----------|-----------------|
| Fecal Calprotectin (mg/kg) | $23.3 \pm 9.6$                  | $240.4 \pm 158.56$                       | $1832.11 \pm 1790.10^{a}$              | KW = 95.5 | 0.000***        |
| CRP (mg/L)                 | $2.1 \pm 0.8$                   | $5.6 \pm 2.3^{b}$                        | $8.0 \pm 2.5^{c,d}$                    | 326.4     | 0.000***        |
| IL-6 level (pg/mL)         | $2.3 \pm 0.8$                   | $3.0 \pm 1.4^{e}$                        | $5.3 \pm 2.1^{f,g}$                    | 135.6     | 0.000**         |
| AOPP (µmol/L)              | $121.8 \pm 21.2$                | $145.1 \pm 34.4^{\rm h}$                 | $199.1 \pm 30.3^{i,j}$                 | 266.0     | 0.000**         |
| GSH (µmol/L)               | $2.8 \pm 0.7$                   | $1.9 \pm 0.6^{k}$                        | $1.1 \pm 0.9^{l,m}$                    | 139.3     | 0.000**         |
| MT (µg/mL)                 | $5.2 \pm 1.0$                   | $7.1 \pm 1.1^{n}$                        | $9.1 \pm 1.5^{o,p}$                    | 305.9     | 0.000**         |
| p53Abs (U/mL)              | $9.3 \pm 1.2$                   | $19.2 \pm 2.8^{\rm q}$                   | $31.1 \pm 3.6^{r,s}$                   | 2260.5    | 0.000**         |

Table 2 Fecal and serological and biomarkers in UC patients infected and not infected with parasites

KW Kruskal-Wallis test

<sup>a</sup>Control vs group III: *p*-value = 0.000\*\*\*

<sup>b</sup>Control vs group II: *p*-value = 0.000\*\*\*

<sup>c</sup>Control vs group III: *p*-value = 0.000\*\*\* <sup>d</sup>Group II vs group III: *p*-value = 0.000\*\*\*

<sup>e</sup>Control vs group III: *p*-value =  $0.00^{**}$ <sup>f</sup>Control vs group III: *p*-value =  $0.000^{***}$ <sup>g</sup>Group II vs group III: *p*-value =  $0.000^{***}$ <sup>h</sup>Control vs group III: *p*-value =  $0.000^{***}$ <sup>i</sup>Control vs group III: *p*-value =  $0.000^{***}$ <sup>i</sup>Control vs group III: *p*-value =  $0.000^{***}$ <sup>k</sup>Control vs group III: *p*-value =  $0.000^{***}$ <sup>h</sup>Control vs group III: *p*-value =  $0.000^{***}$ <sup>n</sup>Control vs group III: *p*-value =  $0.000^{***}$ <sup>n</sup>Control vs group III: *p*-value =  $0.000^{***}$ <sup>n</sup>Control vs group III: *p*-value =  $0.000^{***}$ <sup>o</sup>Control vs group III: *p*-value =  $0.000^{***}$ <sup>g</sup>Group II vs group III: *p*-value =  $0.000^{***}$ <sup>g</sup>Control vs group III: *p*-value =  $0.000^{***}$ <sup>g</sup>Control vs group III: *p*-value =  $0.000^{***}$ 

Table 3A univariate andmultivariate analysis of UCpatients infected and notinfected with parasites

|                    | GII vs GIII         |                 |                       |                 |                        |  |
|--------------------|---------------------|-----------------|-----------------------|-----------------|------------------------|--|
|                    | Univariate analysis |                 | Multivariate analysis |                 |                        |  |
|                    | F-test              | <i>p</i> -value | F-test                | <i>p</i> -value | OR (95% CI)            |  |
| CRP                | 20.3                | 0.000***        | 28.2                  | 0.000****       | 2.3 (1.5 to 3.2)       |  |
| IL6                | 8.1                 | 0.005**         | 14.9                  | 0.000****       | 1.4 (0.7 to 2.2)       |  |
| Fecal calprotectin | 25.4                | 0.000****       | 34.7                  | 0.000****       | 1609(1069.2 to 2149.7) |  |
| AOPP               | 82.6                | 0.000****       | 89.7                  | 0.000****       | 54.3 (42.9 to 65.7)    |  |
| GSH                | 15.2                | 0.000****       | 18.9                  | 0.000****       | -0.7(-1.0  to  0.4)    |  |
| MT                 | 47.5                | 0.000****       | 56.9                  | 0.000****       | 1.9 (1.4 to 2.4)       |  |
| P53                | 302.0               | 0.000****       | 374.4                 | 0.000****       | 11.9 (10.7 to 13.1)    |  |

OR odds ratio, 95% CI 95% confidence interval

\*\*highly significant <0.01, \*\*\*very high significant <0.001

of the mucus barrier and causing severe, prolonged inflammation (Tailford et al. 2015).

Continuous inflammation may lead to a preneoplastic event (Guina et al. 2015). The presented research obtained highly statistically significant increases in AOPP levels.

Our findings are consistent with a prior study that found a rise in AOPP production in inflammatory bowel diseases (Krzystek-Korpacka et al. 2008) and that colon cancer is related to oxidative stress and elevated AOPP levels (Zińczuk et al. 2020). In addition, intestinal parasites,




Fig. 2 Photomicrograph of H&E and immunostained photomicrograph of programmed death ligand (PDLI) and P53 from colonic biopsy ( $\times$ 400). **a** GI with normal colonic mucosa. **b** GII with moderate inflammatory infiltrate with marked crypt distortion. **c** GIII with sever inflammatory infiltrate and marked mucosal ulceration. **d** GII with moderate dysplastic changes (nuclear hyperchromatism and stratification). **e** GIII with sever dysplastic changes (marked nuclear hyperchromatism and pleomorphism). **f** GI with negative PDL1 expression. **g** GII with moderate PDLI expression showing

lium and moderate increased infiltration by the PDL1-positive cells in lamina propria. **h** GIII with strong PDLI expression showing loss of membranous and cytoplasmic expression in colonic epithelium and marked increased infiltration by the PDL1-positive cells in lamina propria. **i** GI with negative P53 expression. **j** GII with moderate dysplastic changes showing moderate P53 expression. **k** GIII with sever dysplastic changes showing strong P53 expression

loss of membranous and cytoplasmic expression in colonic epithe-

especially *Blastocystis* infection, were associated with a substantial oxidative burst, which resulted in oxidative stress (Chandramathi et al. 2010). Our findings show a significant drop in GSH levels in UC patients, with much lower levels in parasite-infected individuals. These results are in line with earlier research, which also demonstrated that GSH system depletion in UC patients causes increased susceptibility to carcinogenic compounds (Scibior et al.

2008). Patients with parasite infections may have reduced levels of GSH, which may encourage an accumulation of free radicals, which in turn cause damage to cell membranes and cellular components (RNA and DNA), resulting in neoplasia. Guevara-Flores et al. (2017) confirmed that in parasites, the enzymes involved in glutathione production and the GSH-dependent antioxidant mechanism are lacking.

Serum p53Ab values in both UC groups were considerably elevated in the current investigation, with significantly higher levels in patients with parasite infections (GIII). p53 is crucial for intestinal type 2 immunity in response to parasite infection (Chang et al. 2021). The commonly accepted concept for elevated serum p53Abs is that a point mutation in the p53 gene causes p53 protein overexpression, causing the release of p53Abs (Yoshizawa et al. 2007). Serum p53 autoantibody levels are used to determine the clinicopathological significance of gastric cancer (Oshima et al. 2020). Moreover, ROS modifies the p53 suppressor gene expression that has a critical role in apoptosis. Consequently, oxidative stress alters gene expression, cell proliferation, and apoptosis, and it is implicated in tumor genesis and development (Barrera 2012). Severe dysplastic alterations confirmed the importance of P53 expression in the colonic mucosa of GIII in our study compared to moderate P53 expression in GII. In our data, the significant rise of MT levels in both UC groups, with higher values in cases with parasitic infections, is consistent with the findings of Tsuji et al. (2013), who found an increase in MT expression in intestinal epithelial cells in IBD. It has been proven that variations in MT expression can be linked to carcinogenesis and cancer development (Krizkova et al. 2018). The probable function of MTs can explain our findings in the immune system and inflammatory processes and shield cells from free radicals and oxidative stress (McNeill et al. 2019). In addition, MTs are indirect regulators of Zn-dependent protein production, such as p53, which is essential for cell function (Bao et al. 2010).

The significant PDL1 expression in GIII in the presented research indicated advanced dysplastic alterations compared to the moderate PDL1 expression in GII. In various tumor types, PD-L1 expression can be controlled by extrinsic and intrinsic signals, including epigenetic modifications, chromosomal alterations, oncogenic and tumor suppressor signals, inflammatory cytokines, and other factors at the genetic, transcriptional, post-transcriptional, translational, and post-translational levels. CNAs on chromosome 9p affecting PD-L1 were identified in colorectal carcinomas (Budczies et al. 2016).

# Conclusion

The current study demonstrates a high frequency of intestinal protozoa, particularly waterborne ones, among UC patients. This results in oxidative stress and oxidative cellular damage, which are critical players in the etiology of the disease and the associated carcinogenetic process. Consequently, UC patients' clinical prognosis can be improved by early screening for parasitic infections for early diagnosis and treatment of protozoan infections. Although our findings suggested a link between parasitic infections and the severity of dysplastic changes in ulcerative colitis patients, we plan to conduct larger research using parasitological molecular diagnostic techniques and genetic profiles of pro-inflammatory cytokines and dysplastic markers in the future to better understand the potential role of intestinal parasites. This could pave the way for a new therapy option for UC patients, perhaps alleviating a potentially fatal condition.

**Abbreviations** UC: ulcerative colitis; FC: fecal calprotectin; p53Abs: anti-p53 antibodies; MTs: metallothioneins; GSH: glutathione; AOPPs: advanced oxidation protein products; CRP: serum C-reactive protein; IL: interleukin; IBD: inflammatory bowel disease; IRB: Institutional Review Board; C. parvum: Cryptosporidium parvum; B. hominis: Blastocystis hominis

Author contribution The research's points were suggested by EFAH; EFAH, NESM, SMF, MNI, BHI, HE, SYM, REH, and EMF planned the methodology; MR analyzed the data; EFAH and NESM wrote the draft. The article's submission was reviewed and approved by all authors.

**Funding** Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).

Data availability Available with the corresponding author when requested

### Declarations

**Ethical approval** The patients and controls provided both informed and written permission. It was registered at the Institutional Review Board (IRB) #9855-9-1-2022.

Consent for publication Not applicable.

Competing interests The authors declare no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

## References

- Alagozlu H, Gorgulb A, Bilgihan A, Tuncerb C, Unal S (2013) Increased plasma levels of advanced oxidation protein products (AOPP) as a marker for oxidative stress in patients with active ulcerative colitis. Clin Res Hepatol Gastroenterol 37(1):80–85
- Aron EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC,

Dolled-Filhart M et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028

- Bao S, Liu MJ, Lee B et al (2010) Zinc modulates the innate immune response in vivo to polymicrobial sepsis through regulation of NF-κB. Am J Physiol Lung Cell Mol Physiol 298(6):L744–L754
- Barrera G (2012) Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol 2012:137289
- Bathe AL, Mavropoulou E, Mechie N-C, Petzold G, Ellenrieder V, Kunsch S et al (2019) Impact of faecal calprotectin measurement on clinical decision-making in patients with Crohn's disease and ulcerative colitis. PLoS One 14(10):e0223893
- Biscaglia G, Latiano A, Castellana S, Fontana R, Gentile A, Latiano T, Corritore G, Panza A, Nardella M, Martino G, Bossa F, Perri F, Mazza T, Andriulli A, Palmieri O (2022) Germline alterations in patients with IBD-associated colorectal cancer. Inflamm Bowel Dis 28(3):447–454. https://doi.org/10.1093/ibd/izab195
- Braidy N, Zarka M, Jugder B-E, Welch J, Jayasena T, Chan DKY, Sachdev P, Bridge W (2019) The Precursor to Glutathione (GSH), γ-Glutamylcysteine (GGC), Can ameliorate oxidative damage and neuroinflammation induced by Aβ40 oligomers in human astrocytes. Front Aging Neurosci 11:177
- Budczies J, Bockmayr M, Denkert C, Klauschen F, Gröschel S, Darb-Esfahani S et al (2016) Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274)
  - associations with gene expression, mutational load, and survival. Genes Chromosomes Cancer 55:626–639
- Cekin AH, Cekin Y, Adakan Y, Tasdemir E, Koclar FG, Yolcular BO (2012) Blastocystosis in patients with gastrointestinal symptoms: a case-control study. BMC Gastroenterol 12:122. https:// doi.org/10.1186/1471-230X-12-122
- Chandramathi S, Suresh K, Shuba S, Mahmood A, Kuppusamy U (2010) High levels of oxidative stress in rats infected with *Blastocystis hominis*. Parasitology 137(4):605–611
- Chang CY, Wang J, Zhao Y et al (2021) Tumor suppressor p53 regulates intestinal type 2 immunity. Nat Commun 12:3371. https:// doi.org/10.1038/s41467-021-23587-x
- Cioffi M, Riegler G, Vietri MT, Pilla P, Caserta L, Carratù R, Sica V, Molinari AM (2004) Serum p53 antibodies in patients affected with ulcerative colitis. Inflamm Bowel Dis 10:606–611
- Cousins RJ (1991) Measurement of human metallothionein by enzymelinked immunosorbent assay. Methods Enzymol 205:131–140
- Guevara-Flores A, Martínez-González JJ, Rendón JL, Del Arenal IP (2017) The architecture of thiol antioxidant systems among invertebrate parasites. Molecules 22:259
- Guina T, Biasi F, Calfapietra S, Nano M, Poli G (2015) Inflammatory and redox reactions in colorectal carcinogenesis. Ann N Y Acad Sci 1340:95–103
- Hamouda HE, Zakaria SS, Ismail SA, Khedr MA, Mayah WW (2011) P53 antibodies, metallothioneins, and oxidative stress markers in chronic ulcerative colitis with dysplasia. World J Gastroenterol 17(19):2417–2423
- Henricksen SA, Pohlenz JF (1981) Staining of cryptosporidia by a modified Ziehl-Neelsen technique. Acta Vet Sacnd 22:594–596
- IBM Corp (2015) IBM SPSS statistics for windows, version 23.0. IBM Corp, Armonk, NY
- Iyer VH, Augustine J, Pulimood AB, Ajjampur SS, Ramakrishna BS (2013) Correlation between coinfection with parasites, cytomegalovirus, and *Clostridium difficile* and disease severity in patients with ulcerative colitis. Indian J Gastroenterol. 32:115–118
- Jakubowska K, Pryczynicz A, Piekarska VD, Famulski W, Ustymowicz KG (2016) Immunohistochemical expression and serum level of survivin protein in colorectal cancer patients. Oncol Lett 12(5):3591–3597. https://doi.org/10.3892/ol.2016.5075
- Jess T, Rungoe C, Peyrin-Biroulet L (2012) Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of populationbased cohort studies. Clin Gastroenterol Hepatol 10(6):639–645

- Jung S, Wu C, Eslami Z, Tanguay S, Aprikian A, Kassouf W et al (2014) The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6,P53, Cd138, and Her2/Neu. Ann Diagn Pathol 18(1):27–32
- King M (1975) A medical laboratory for developing countries, vol 15. ELBS, Oxford University Press, pp 45–55
- Kirsch DG, Kastan MB (1998) Tumor-suppressor p53: implications for tumor development and prognosis. J Clin Oncol 16:3158–3168
- Krizkova S, Kepinska M, Emri G, Eckschlager T, Stiborova M, Pokorna P, Heger Z, Adam V (2018) An insight into the complex roles of metallothioneins in malignant diseases with emphasis on (sub)isoforms/isoforms and epigenetics phenomena. Pharm Ter 183:90–117
- Krizkova S, Masarik M, Majzlik P, Kukacka J, Kruseova J, Adam V et al (2010) Serum metallothionein in newly diagnosed patients with childhood solid tumours. Acta Biochim Pol 57:561
- Krzystek-Korpacka M, Neubauer K, Berdowska I, Boehm D, Zielinski B, Petryszyn P, Terlecki G, Paradowski L, Gamian A (2008) Enhanced formation of advanced oxidation protein products in IBD. Inflamm Bowel Dis 14:794–802
- Liebl MC, Hofmann TG (2021) The role of p53 signaling in colorectal cancer. Cancers 13(9):2125
- Liu Z, Ren Z, Zhang J, Chuang C, Kandaswamy E, Zhou T, Zuo L (2018) Role of ROS and nutritional antioxidants in human diseases. Front Physiol 9:477
- Mavropoulou E, Mechie NC, Knoop R, Petzold G, Ellenrieder V, Kunsch S, Pilavakis Y, Amanzada A (2020) Association of serum interleukin-6 and soluble interleukin-2-receptor levels with disease activity status in patients with inflammatory bowel disease: a prospective observational study. PLoS One 15(5):e0233811
- McNeill RV, Mason AS, Hodson ME, Catto JWF, Southgate J (2019) Specificity of the metallothionein-1 response by cadmiumexposed normal human urothelial cells. Int J Mol Sci 20:1–18
- Morgenstern I, Raijmakers MT, Peters WH, Hoensch H, Kirch W (2003) Homocysteine, cysteine, and glutathione in human colonic mucosa: elevated levels of homocysteine in patients with inflammatory bowel disease. Dig Dis Sci 48:2083–2090
- Mostafa NE, Abdel Hamed EF, Fawzy EM, Zalat RS, Rashed HE, Mohamed SY (2018) The new trend in the treatment of experimental cryptosporidiosis and the resulting intestinal dysplasia. Colorectal Cancer 7(4):CRC06
- Na H, Liu X, Li X, Zhang X, Wang Y, Wang Z, Yuan M, Zhang Y, Ren S, Zuo Y (2017) Novel roles of DC-SIGNR in colon cancer cell adhesion, migration, invasion, and liver metastasis. J Hematol Oncol 10:28
- Olén O, Erichsen R, Sachs MC, Pedersen L, Halfvarson J, Askling J et al (2020) Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. Lancet 395(10218):123–131
- Oshima Y, Suzuki T, Yajima S et al (2020) Serum p53 antibody: useful for detecting gastric cancer but not for predicting prognosis after surgery. Surg Today 50:1402–1408
- Pence M, Singla MB, Armbruster SP (2015) A Case for pathologic Blastocystis hominis. Am J Gastroenterol 11:165
- Pestechian N, Tavakoli S, Adibi P, Safa AH, Parsaei R, Yousefi HA (2021) Prevalence of intestinal protozoan infection in patients with ulcerative colitis (UC) in Isfahan, Iran. Int J Prev Med 12:114. https://doi.org/10.4103/ijpvm.IJPVM\_471\_19
- Pestehchian N, Nazari M, Haghighi A, Salehi M, Yosefi HA, Khosravi N (2015) Prevalence of intestinal parasitic infection among inhabitants and tribes of Chelgerd, Iran, 2008-2009. J Clin Diagn Res 9:LC01–LC04
- Romano M, De Francesco F, Zarantonello L, Ruffolo C, Ferraro GA, Zanus G et al (2016) From inflammation to cancer in inflammatory bowel disease: molecular perspectives. Anticancer Res 36(4):1447–1460

- Satsangi J, Silverberg MS, Vermeire S, Colombel JF (2006) The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55:749–753
- Sawant M, Baydoun M, Creusy C, Chabé M, Viscogliosi E, Certad G, Benamrouz-Vanneste S (2020) *Cryptosporidium* and colon cancer: cause or consequence? Microorganisms 8(11):1665
- Scibior D, Skrzycki M, Podsiad M, Czeczot H (2008) Glutathione level and glutathione-dependent enzyme activities in blood serum of patients with gastrointestinal tract tumors. Clin Biochem 41:852–858
- Sedlak J, Lindsay RH (1968) Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 25:192–205
- Silverberg MS, Satsangi J, Ahmad T et al (2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19(suppl A):5–36
- Sulżyc-Bielicka V, Kołodziejczyk L, AdamskaM SB, Jaczewska S, Safranow K, Bielicki P, Kładny J, Bielicki D (2021) Colorectal cancer and *Blastocystis sp.* Infection. Parasit Vectors 14:200
- Sulżyc-Bielicka V, Kołodziejczyk L, Jaczewska S, Bielicki D, Safranow K, Bielicki P, Kładny J, Rogowski W (2018) Colorectal cancer and *Cryptosporidium* spp. Infection. PLoS One 13(4):e0195834
- Taghipour A, Rayatdoost E, Bairami A et al (2022) Are *Blastocystis hominis* and *Cryptosporidium spp*. playing a positive role in colorectal cancer risk? A systematic review and meta-analysis. Infect Agents. Cancer 17:32
- Tailford LE, Crost EH, Kavanaugh D, Juge N (2015) Mucin glycan foraging in the human gut microbiome. Front Genet 6:81
- Tian T, Wang Z, Zhang J (2017) Pathomechanisms of oxidative stress in inflammatory bowel disease and potential antioxidant therapies. Oxid Med Cell Longev 2017:4535194
- Toychiev A, Navruzov B, Pazylova D, Davis N, Badalova N, Osipova S (2021) Intestinal protozoa and helminths in ulcerative colitis and the influence of anti-parasitic therapy on the course of the disease. Acta Trop 213:105755

- Truant AL, Elliott SH, Kelly MT, Smith JH (1981) Comparison of formalin-ethyl ether sedimentation, formalin-ethyl acetate sedimentation, and zinc sulfate flotation techniques for detection of intestinal parasites. J Clin Microbiol 13(5):882–884
- Tsuji T, Naito Y, Takagi T, Kugai M, Yoriki H, Horie R et al (2013) Role of metallothionein in murine experimental colitis. Int J Mol Med 31:1037–1046
- Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF (2017) Ulcerative colitis. Lancet 389:1756–1770
- Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woolf S, Johnson D, Kirk L, Litin S, Simmang C (2003) Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 124:544–560
- Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillère- Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers P, Drüeke T, Descamps-Latscha B (1998) Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161:2524–2532
- Yoshizawa S, Matsuoka K, Inoue N, Takaishi H, Ogata H, Iwao Y, Mukai M, Fujita T, Kawakami Y, Hibi T (2007) Clinical significance of serum p53 antibodies in patients with ulcerative colitis and its carcinogenesis. Inflamm Bowel Dis 13:865–873
- Zińczuk J, Maciejczyk M, Zaręba K, Pryczynicz A, Dymicka-Piekarska V, Kamińska J, Koper-Lenkiewicz O, Matowicka-Karna J, Kędra B, Zalewska A, Guzińska-Ustymowicz K (2020) Pro-oxidant enzymes, redox balance and oxidative damage to proteins, lipids and DNA in colorectal cancer tissue. Is oxidative stress dependent on tumour budding and inflammatory infiltration? Cancers 12:1636

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.